Chevallard Daniel R.'s Form 4 filing
LENZ Therapeutics, Inc. (LENZ) · filed Nov 7, 2025
- Accession no.
- 0001815776-25-000072
- Filed
- Nov 7, 2025
- Trade date
- Nov 7, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $50.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chevallard Daniel R.CIK 0001706176 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | Common Stock | PPurchaseAcquired | +20 | $22.71 | +$454.2 | 3,208 | Direct | |
| Nov 7, 2025 | Common Stock | PPurchaseAcquired | +2,178 | $22.76 | +$49,571.28 | 5,386 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.